Literature DB >> 19843088

Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro.

N K Banda1, B Levitt, A K Wood, K Takahashi, G L Stahl, V M Holers, W P Arend.   

Abstract

The alternative pathway (AP) of complement alone is capable of mediating immune complex-induced arthritis in the collagen antibody-induced arthritis (CAIA) model in mice. Whether the classical pathway (CP) or lectin pathway (LP) alone can mediate CAIA is not known. Using mice genetically deficient in different complement components, our results reported herein establish that the CP and LP alone are each incapable of mediating CAIA. A lower level or absence of C3 and/or C5 activation by the CP may be possible explanations for the importance of the AP in CAIA and in many murine models of disease. In addition, other investigators have reported that CP C5 convertase activity is absent in mouse sera. To address these questions, we employed an in vitro system of adherent immunoglobulin (Ig)G-induced complement activation using plates coated with murine anti-collagen monoclonal antibody (mAb). These experiments used complement-deficient mouse sera and wild-type mouse or normal human sera under conditions inactivating either the CP (Ca(++) deficiency) or the AP (mAb inhibitory to factor B). Robust generation of both C3a and C5a by either the AP or CP alone were observed with both mouse and human sera, although there were some small differences between the species of sera. We conclude that neither the CP nor LP alone is capable of mediating CAIA in vivo and that mouse sera exhibits a high level of IgG-induced C5a generation in vitro through either the CP or AP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19843088      PMCID: PMC2802700          DOI: 10.1111/j.1365-2249.2009.04035.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

Review 1.  Structure/function of C5 convertases of complement.

Authors:  N Rawal; M K Pangburn
Journal:  Int Immunopharmacol       Date:  2001-03       Impact factor: 4.932

2.  Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis.

Authors:  Max Albert Hietala; Kutty S Nandakumar; Linda Persson; Susann Fahlén; Rikard Holmdahl; Marcela Pekna
Journal:  Eur J Immunol       Date:  2004-04       Impact factor: 5.532

Review 3.  The complement system in regulation of adaptive immunity.

Authors:  Michael C Carroll
Journal:  Nat Immunol       Date:  2004-10       Impact factor: 25.606

4.  A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice.

Authors:  Joshua M Thurman; Damian M Kraus; Guillermina Girardi; Dennis Hourcade; Hee J Kang; Pamela A Royer; Lynne M Mitchell; Patricia C Giclas; Jane Salmon; Gary Gilkeson; V Michael Holers
Journal:  Mol Immunol       Date:  2005-01       Impact factor: 4.407

5.  Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies.

Authors:  Nirmal K Banda; Allyson K Wood; Kazue Takahashi; Brandt Levitt; Pauline M Rudd; Louise Royle; Jodie L Abrahams; Gregory L Stahl; V Michael Holers; William P Arend
Journal:  Arthritis Rheum       Date:  2008-10

Review 6.  Properdin: New roles in pattern recognition and target clearance.

Authors:  Claudia Kemper; Dennis E Hourcade
Journal:  Mol Immunol       Date:  2008-08-08       Impact factor: 4.407

7.  Complement deficiency ameliorates collagen-induced arthritis in mice.

Authors:  Max Albert Hietala; Ing-Marie Jonsson; Andrej Tarkowski; Sandra Kleinau; Marcela Pekna
Journal:  J Immunol       Date:  2002-07-01       Impact factor: 5.422

8.  Targeting of complement to tumor cells by heteroconjugates composed of antibodies and of the complement component C3b.

Authors:  Y Reiter; Z Fishelson
Journal:  J Immunol       Date:  1989-04-15       Impact factor: 5.422

Review 9.  Evolution of the lectin-complement pathway and its role in innate immunity.

Authors:  Teizo Fujita
Journal:  Nat Rev Immunol       Date:  2002-05       Impact factor: 53.106

10.  Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.

Authors:  M K Pangburn; R D Schreiber; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

View more
  23 in total

1.  The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models.

Authors:  Masha Fridkis-Hareli; Michael Storek; Eran Or; Richard Altman; Suresh Katti; Fang Sun; Tao Peng; Jeff Hunter; Krista Johnson; Yi Wang; Ante S Lundberg; Gaurav Mehta; Nirmal K Banda; V Michael Holers
Journal:  Mol Immunol       Date:  2018-12-01       Impact factor: 4.407

2.  Essential role of complement mannose-binding lectin-associated serine proteases-1/3 in the murine collagen antibody-induced model of inflammatory arthritis.

Authors:  Nirmal K Banda; Minoru Takahashi; Brandt Levitt; Magdalena Glogowska; Jessica Nicholas; Kazue Takahashi; Gregory L Stahl; Teizo Fujita; William P Arend; V Michael Holers
Journal:  J Immunol       Date:  2010-09-24       Impact factor: 5.422

3.  Mechanisms of mannose-binding lectin-associated serine proteases-1/3 activation of the alternative pathway of complement.

Authors:  Nirmal K Banda; Minoru Takahashi; Kazue Takahashi; Gregory L Stahl; Stephanie Hyatt; Magdalena Glogowska; Timothy A Wiles; Yuichi Endo; Teizo Fujita; V Michael Holers; William P Arend
Journal:  Mol Immunol       Date:  2011-09-23       Impact factor: 4.407

4.  Interaction of extremophilic archaeal viruses with human and mouse complement system and viral biodistribution in mice.

Authors:  Linping Wu; Kristine Buch Uldahl; Fangfang Chen; Halli Benasutti; Deborah Logvinski; Vivian Vu; Nirmal K Banda; Xu Peng; Dmitri Simberg; Seyed Moein Moghimi
Journal:  Mol Immunol       Date:  2017-08-30       Impact factor: 4.407

5.  Mannan-Binding Lectin-Associated Serine Protease 1/3 Cleavage of Pro-Factor D into Factor D In Vivo and Attenuation of Collagen Antibody-Induced Arthritis through Their Targeted Inhibition by RNA Interference-Mediated Gene Silencing.

Authors:  Nirmal K Banda; Sumitra Acharya; Robert I Scheinman; Gaurav Mehta; Marilyne Coulombe; Minoru Takahashi; Hideharu Sekine; Steffen Thiel; Teizo Fujita; V Michael Holers
Journal:  J Immunol       Date:  2016-10-05       Impact factor: 5.422

6.  The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization.

Authors:  Bärbel Rohrer; Beth Coughlin; Kannan Kunchithapautham; Qin Long; Stephen Tomlinson; Kazue Takahashi; V Michael Holers
Journal:  Mol Immunol       Date:  2011-01-22       Impact factor: 4.407

7.  A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA.

Authors:  Gaurav Mehta; Robert I Scheinman; V Michael Holers; Nirmal K Banda
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

8.  A recombinant vaccine effectively induces c5a-specific neutralizing antibodies and prevents arthritis.

Authors:  Kutty Selva Nandakumar; Asa Jansson; Bingze Xu; Niclas Rydell; Parvin Ahooghalandari; Lars Hellman; Anna M Blom; Rikard Holmdahl
Journal:  PLoS One       Date:  2010-10-20       Impact factor: 3.240

9.  A single functional group substitution in c5a breaks B cell and T cell tolerance and protects against experimental arthritis.

Authors:  Christoph Kessel; Kutty S Nandakumar; Francis B Peters; Varun Gauba; Peter G Schultz; Rikard Holmdahl
Journal:  Arthritis Rheumatol       Date:  2014-03       Impact factor: 10.995

10.  New insights into disease-specific absence of complement factor H related protein C in mouse models of spontaneous autoimmune diseases.

Authors:  Gaurav Mehta; Viviana P Ferreira; Christine Skerka; Peter F Zipfel; Nirmal K Banda
Journal:  Mol Immunol       Date:  2014-07-15       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.